Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800CW image-guided Mohs surgery for cutaneous squamous cell carcinoma
NL-OMON23751Phase 1Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW and cetuximab in cutaneous squamous cell carcinoma (cSCC), sponsored by University Medical Center Groningen. Primary endpoints: Macroscopic fluorescent signal and tracer distribution, Quantification of fluorescent signals by spectroscopy and 1 more. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
cetuximab-IRDye 800CWcetuximab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON23751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23751.